Published on : Jun 24, 2020
ResearchMoz.us has announced the addition of a report, titled “Syphilis Immunoassay Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027”. The study provides a granular assessment of key growth dynamics, major clinical avenues, imminent investment pockets, and trends shaping the future research and development activities. The various assessments also offer insights into the share and size of key product and technology types, and also offer analysis of new avenues in key regional markets.
Advent of automated immunoassays in lab infrastructure has been crucial development shaping the evolution trajectories in the syphilis immunoassay diagnostics market. Continuous advancements in analyzers and efforts of industry stakeholders to mainstream the technologies in the serological testing have catalyzed the growth of the market. Providers of diagnostic technologies are engaged in constantly researching on improving the diagnostic performances of their propriety assay technologies. The trend is evident in emerging economies, notably in China. This has been offering substantial impetus to the growth momentum in the market. Such players are also focusing on the sensitivity and specificity of the assays.
Advent of immunoassays that are easy to use, allows automation, and enables high-throughput detection has been expanding the prospects in the syphilis immunoassay diagnostics market. Such technologies are being mainstreamed in the routine screening of serum samples. Resultantly, automated treponemal tests have gathered some steam.
The syphilis immunoassay diagnostics market is in incipient stages, and is expected to rise at a promising single-digit CAGR from 2019 to 2027. In healthcare system around the world, incessant efforts have been undertaken by public healthcare and private players are focusing on identifying high-risk populations, notably those infected by HIV. The substantial morbidity and mortality in untreated syphilis is numerous developing and developed countries has spurred research in immunoassays diagnostics for the disease. The need for such technologies has been reiterated by national syphilis surveillance and control strategies by the WHO. A case in point is ‘Global Health Sector Strategy on Sexually Transmitted Infections (STIs) 2016–2021’. In numerous countries, governments are focusing on developing Spectrum-STI models.
Among the various regions, North America is expected to expand at promising growth rate during 2019 – 2027, and is expected to offer substantial lucrative avenues. Countries in the region has seen the mandatory screening of syphilis, especially among pregnant women. Growing uptake of tests among blood donors in the region has also catalyzed prospects of the regional market. Comprehensive syphilis screening and treatments are also prevalent in Europe, which is expected to offer massive momentum to the expansion of the global syphilis immunoassay diagnostics market. Developed markets are seeing intensive research in cell-based research. Meanwhile, Africa is expected to be a promising market.
Get Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=2690573
Among the various product types, kits and reagents have witnessed vast uptake in the market. Among the various technologies, ELISA dominates the global market in 2018. However, in coming years, CLIA is anticipated to gain share in the global market. Among the various end users, blood banks are expected to witness considerable demands for syphilis immunoassay diagnostics market. Further, blood banks are expected to rise at promising CAGR during 2019 – 2027. Large patient pool is expected to reinforce prospects in the market.
The competitive landscape in the syphilis immunoassay diagnostics market is characterized by high degree of fragmentation. They are also expanding their distribution channels and also focusing on specific innovations. Some of the promising players in the market are Fujirebio, bioMérieux SA, Ortho Clinical Diagnostics, Abbott Laboratories, DiaSorin S.p.A., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company Bio-Rad Laboratories, and Danaher.